Despite extensive evidence showing upregulation of G6PD expression and activity across various tumors, its regulation through acetylation/deacetylation by KAT9 and SIRT2 has not yet been studied in hypoxic glioma cells. This evidence concerns the gene G6PD and central nervous system cancer.